Combination antiresorptive and osteoanabolic therapy for osteoporosis: We are not there yet

Current Medical Research and Opinion

Volumn 27, Issue 9, 2011, Pages 1705-1707

  Cusano, Natalie E ^a   Bilezikian, John P ^a  

^a Columbia University ^*  (United States)

Author keywords

Alendronate; Osteoporosis; PTH(1 84); Risedronate; Sequential therapy; Teriparatide

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BONE DENSITY CONSERVATION AGENT; OSTEOANABOLIC AGENT; PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE DENSITY; BONE STRUCTURE; BONE TURNOVER; COMBINATION CHEMOTHERAPY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFECT; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FRAGILITY FRACTURE; HUMAN; MONOTHERAPY; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; OSTEOSARCOMA; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; TREATMENT OUTCOME; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; HUMANS; OSTEOPOROSIS;

EID: 80051771412     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.599837     Document Type: Review

References (20)

1. Boonen S, Millisen K, Gielen E, et al. Sequential therapy in the treatment of osteoporosis. Curr Med Res Opin 2011;27:1149-1155
2. Lindsay R, Cosman F, Zhou H, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006;21:366-373
3. Bilezikian JP. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 2008;6:24-30
4. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-1443
5. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352 (Pubitemid 29483192)
6. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-2039 (Pubitemid 350106710)
7. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009;60:3346-3355
8. Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19:745-751 (Pubitemid 41094385)
9. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008;93:3785-3793
10. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-1215 (Pubitemid 37152030)
11. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-1226 (Pubitemid 37152031)
12. Finkelstein JS, Wyland JJ, Lee H, et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2010;95:1838-1845
13. Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005;20:1905-1911 (Pubitemid 41532775)
14. Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011;26:503-511
15. Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004; 15:992-997 (Pubitemid 40064654)
16. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005; 353:555-565 (Pubitemid 41138937)
17. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005;16:510-516
18. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002; 30:312-321 (Pubitemid 34556102)
19. Harper KD, Krege JH, Marcus R, et al. Comments on initial experience with teriparatide in the United States. Curr Med Res Opin 2006;22:1927 (Pubitemid 44663397)
20. Harper KD, Krege JH, Marcus R, et al. Osteosarcoma and teriparatide? J Bone Miner Res 2007;22:334 (Pubitemid 46167804)